Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma

Cancer

Volumn 78, Issue 4, 1996, Pages 789-793

  Miller, Antonius A ^a   Lipton, Allan ^b   Craig Henderson, I ^c   Navari, Rudolph ^d   Mulagha, Mary T ^e   Cooper, Judy ^e  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Simon Williamson Clinic   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aromatase inhibition; breast carcinoma; clinical pharmacology; fadrozole hydrochloride

Indexed keywords

FADROZOLE;

ADULT; ANXIETY NEUROSIS; ARTICLE; BREAST CARCINOMA; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; SWEATING; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FADROZOLE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 0029761970     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960815)78:4<789::AID-CNCR15>3.0.CO;2-R     Document Type: Article

References (11)

1. Kennedy BJ. Hormonal therapies in breast cancer. Semin Oncol 1974:2:119-30.
2. Henderson IC. Endocrine therapy in metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW editors. Breast diseases. Philadelphia: J.B. Lippincott, 1987:398-428.
3. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:22-65.
4. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978;47:1257-65.
5. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, et al. Tamoxifen versus aminoglutethimide in advanced breast cancer: a randomized cross-over trial. BMJ 1981;283:1432-4.
6. Demers LM, Melby JC, Wilson TE, Lipton A, Harvey HA, Santen RJ. The effects of CGS 16949A, an aromatase inhibitor, on adrenal mineralocorticoid biosynthesis. J Clin Endocrinol Metab 1990;70:1162-6.
7. Steele RE, Mellor LB, Sawyer WK, Wasvary JM, Browne LJ. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor, CGS 16949A. Steroids 1987;50:146-61.
8. Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, et al. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab 1991;73:99-106.
9. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981;47:207-14.
10. Hayward JL, Carbone PP, Henson JC, Kumaoha S, Segaloff A, Reubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977;39:1289-94.
11. Stein RC, Dowsett M, Davenport J, Hedley A, Ford HT, Gazet JC, et al. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res 1990;50:1381-4.